Next‐generation sequencing‐based studies have uncovered the CCA genetic landscape,3 revealing the shared recurrent mutations in TP53, ARID1A, KRAS, SMAD4, etc. However, the complete understanding of genetic aberrations‐driven tumor phenotypes remains ambiguous. The gene discussed is TP53; the disease is cholangiocarcinoma.